{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:58:51Z","timestamp":1790276331763,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>This article presents 3 cases of immunocompromised patients for whom therapeutic drug monitoring of ganciclovir in combination with cytomegalovirus viral load measurement was used to guide treatment. The first patient is diagnosed with thymoma A, the second is a heart transplant recipient, and the third is an HIV-positive patient. These patients were all diagnosed with cytomegalovirus and treated with ganciclovir. Our case studies illustrate how therapeutic drug monitoring\u2013guided dosing can be helpful in the management of these complex cases.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000598","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T01:18:47Z","timestamp":1548811127000},"page":"107-110","source":"Crossref","is-referenced-by-count":23,"title":["Ganciclovir Therapeutic Drug Monitoring: A Case Series"],"prefix":"10.1097","volume":"41","author":[{"given":"Anne-Grete","family":"M\u00e4rtson","sequence":"first","affiliation":[{"name":"Clinical Pharmacy and Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Touw","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Damman","sequence":"additional","affiliation":[{"name":"Cardiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Bakker","sequence":"additional","affiliation":[{"name":"Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Oude Lansink-Hartgring","sequence":"additional","affiliation":[{"name":"Critical Care,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjip","family":"van der Werf","sequence":"additional","affiliation":[{"name":"Pulmonary Diseases and Tuberculosis,"},{"name":"Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Knoester","sequence":"additional","affiliation":[{"name":"Medical Microbiology and Infection Control, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jcp.56.1.12","article-title":"What is Good's syndrome? Immunological abnormalities in patients with thymoma","volume":"56","author":"Kelleher","year":"2003","journal-title":"J Clin Pathol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clim.2010.01.006","article-title":"Good's syndrome remains a mystery after 55 years: a systematic review of the scientific evidence","volume":"135","author":"Kelesidis","year":"2010","journal-title":"Clin Immunol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.00892-13","article-title":"Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients","volume":"58","author":"Horvatits","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements","volume":"48","author":"Perrottet","year":"2009","journal-title":"Clin Pharmacokinet."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antivir Res."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200544050-00003","article-title":"Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients","volume":"44","author":"Wiltshire","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/340101","article-title":"Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients","volume":"34","author":"Mylonakis","year":"2002","journal-title":"Clin Infect Dis."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMe1401567","article-title":"Taming the transplantation troll by targeting terminase","volume":"370","author":"Griffiths","year":"2014","journal-title":"N Engl J Med."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007691-200402000-00014","article-title":"Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring?","volume":"26","author":"Scott","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jchromb.2007.01.045","article-title":"Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples","volume":"852","author":"Perrottet","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R17-20230814","article-title":"Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study","volume":"2015","author":"Peredo","year":"2015","journal-title":"BMJ Case Rep."},{"key":"R18-20230814","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piw008","article-title":"Therapeutic drug monitoring of ganciclovir treatment for cytomegalovirus infections among immunocompromised children","author":"Stockmann","year":"2016","journal-title":"J Pediatr Infect Dis Soc."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijantimicag.2014.03.001","article-title":"Variable ganciclovir concentrations in a critically ill patient receiving continuous renal replacement therapy and plasma exchange?","volume":"43","author":"Nunez-Nunez","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003495-200161080-00016","article-title":"Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201904000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:34:13Z","timestamp":1692052453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201904000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000598","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}